Gustave Roussy Cancer Campus-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2023

  1. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

2022

  1. Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

    Neuroendocrinology, Vol. 112, Núm. 12, pp. 1155-1167

2021

  1. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

  2. Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451

    Annals of oncology : official journal of the European Society for Medical Oncology

  3. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    Annals of Oncology, Vol. 32, Núm. 4, pp. 439-451

  4. Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2019

  1. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

    Neuroendocrinology

2016

  1. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas

    Neuroendocrinology

2014

  1. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

    European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505